Diabetes
Refine Search
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
The Malaysian business of Biocon subsidiary Biocon Biologics has agreed a deal to supply its recombinant human insulin brand Insugen to the country’s healthcare system. 26 April 2022
Biotechnology
As well as several novel drug recommendations at its April meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) backed the extension of therapeutic indications for seven already marketed medicines. 23 April 2022
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim is always the last pharma major to present its annual financial results, and this year’s results have been worth the wait. 6 April 2022
Pharmaceutical
Germany’s Bayer has announced late-breaking data from prespecified exploratory subgroup analyses of FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD trials. 5 April 2022
Biosimilars
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorization for Inpremzia, a biosimilar version of Actrapid (human insulin). 1 April 2022
Pharmaceutical
Due to Russia’s military invasion of the Ukraine, global pharma companies are massively refusing to conduct clinical trials of their drugs in Russia, which means that the launch of these drugs in the local market will be impossible 19 March 2022
Generics
To help combat the nationwide insulin affordability crisis, Civica Rx, a non-profit generic pharmaceutical company, has launched its Insulin Initiative with the JDRF. The initiative aims to drive affordability and accessibility for all Americans, regardless of insurance status. 17 March 2022
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Kerendia (finerenone) (10mg or 20mg) in Great Britain, an oral, first-in-class non-steroidal, selective mineralocorticoid receptor (MR) antagonist, for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. 9 March 2022
Generics
USA-based Civica Rx, the non-profit generic drugmaker set up by hospital systems in 2018 to help counter rising prices and supply shortages, has announced plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at significantly lower prices than insulins currently on the market. 4 March 2022
Pharmaceutical
Merck KGaA hailed a year of record growth in 2021. 3 March 2022
Pharmaceutical
In a European worksharing procedure (WSP), Germany’s Merck KGaA Glucophage (metformin hydrochloride) and its immediate and extended release versions have been approved as the first oral anti-diabetic medication to be used safely during pregnancy. 28 February 2022
Pharmaceutical
A new broader label for heart med Jardiance (empagliflozin) will help developers Eli Lilly and Boehringer Ingelheim extend the increasingly lucrative franchise. 25 February 2022
Pharmaceutical
Eris Lifesciences is foraying into an oligopolistic insulin market with its own insulin brand this month. 24 February 2022
Biotechnology
The World Health Organization (WHO), the Republic of Korea and the WHO Academy have established a global biomanufacturing training hub that will serve all low- and middle-income countries wishing to produce biologicals, such as vaccines, insulin, monoclonal antibodies and cancer treatments. 24 February 2022
Biotechnology
US drugmaker Eli Lilly has announced the launch of the Lilly Institute for Genetic Medicine with an investment of approximately $700 million to establish a facility at a new site in the Boston Seaport. 23 February 2022
Pharmaceutical
Following a December positive opinion from the European Medicines Agency’s advisory committee, the European Commission has granted marketing authorization in the European Union (EU) for Kerendia (finerenone). 22 February 2022
Biotechnology
Influential pricing watchdog ICER - the Institute for Clinical and Economic Review - has released a final report into the cost-effectiveness of Eli Lilly’s GLP-1 agonist tirzepatide. 15 February 2022
Biotechnology
US biotechnology company Kallyope, which is focused on identifying and developing therapeutics involving the gut-brain axis, today announced the closing of a $236 million Series D financing co-led by Mubadala Investment Company and The Column Group, along with participation from other new and existing investors. 15 February 2022
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca closed nearly 4% higher on Thursday after presenting stellar fourth-quarter and full-year 2021 financial results. 10 February 2022
Pharmaceutical
Danish diabetes giant Novo Nordisk has reported net sales of 140 billion kroner ($21.3 billion) in 2021, an 11% increase from the year before. 2 February 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze